Is there evidence for use of tebipenem in non-UTI indications?

Comment by InpharmD Researcher

Limited evidence is available regarding tebipenem for non-urinary tract infections, with most clinical efficacy data involving the Japanese tebipenem pivoxil formulation (Orapenem). Clinical studies evaluating this formulation reported favorable outcomes in pediatric respiratory and otolaryngological infections and adult otolaryngological infections, including an overall clinical efficacy rate of 94.0% in pediatric patients with pneumonia, otitis media, or sinusitis. For the U.S. tebipenem pivoxil hydrobromide (Utebzi) formulation, available human evidence primarily involves pharmacokinetic studies demonstrating pulmonary epithelial lining fluid and soft-tissue penetration, including approximately 90% tissue penetration in patients with diabetic foot infections, without establishing clinical efficacy for these indications. Additional preclinical studies demonstrated antibacterial activity in murine lung and thigh infection models, while potential use in intra-abdominal infections has been proposed based on microbiological activity. Overall, although these findings suggest potential utility in nonurinary infections, the applicability of Japanese clinical efficacy data to the U.S. formulation remains uncertain, and clinical studies establishing its efficacy for these indications are lacking.
Background

A 2025 narrative review evaluated the antimicrobial activity, pharmacokinetics/pharmacodynamics, and clinical applications of oral penems and carbapenems, including tebipenem, for bacterial infections. For nonurinary indications, the review described clinical experience with tebipenem in pediatric respiratory tract infections using the Japanese formulation and pharmacokinetic studies demonstrating pulmonary epithelial lining fluid penetration and soft-tissue penetration in patients with diabetic foot infections using the U.S.-developed tebipenem pivoxil hydrobromide formulation. The authors also identified potential applications in intra-abdominal infections based on tebipenem's broad Gram-negative and anaerobic activity, although clinical trials evaluating its efficacy for this indication were lacking. [1]

Background References: [1] Sayood S, Neuner E, Dumm R, Gandra S. The oral penems and carbapenems. Clin Microbiol Rev. 2025;38(4):e0004224. doi:10.1128/cmr.00042-24
Literature Review

A search of the published medical literature revealed 5 studies investigating the researchable question:

Is there evidence for use of tebipenem in non-UTI indications?

Level of evidence

B - One high-quality study or multiple studies with limitations  Read more→



Please see Tables 1-5 for your response.


Pharmacokinetics and soft-tissue distribution of tebipenem pivoxil hydrobromide using microdialysis: a study in healthy subjects and patients with diabetic foot infections
Design

Single-centre, open-label, observational pharmacokinetic study

N= 12

Objective To assess tebipenem steady-state pharmacokinetics in the skin and soft tissue in healthy subjects and infected patients with diabetes using in vivo microdialysis
Study Groups

Healthy subjects (n= 6)

Infected patients with diabetic foot infection (DFI; n= 6)

Inclusion Criteria Infected patients over 18 years old with a documented history of diabetes mellitus type 1 or type 2 requiring treatment with antihyperglycaemic therapy and an active complicated skin and soft-tissue infection as defined by PEDIS Grade 2 or 3 infections
Exclusion Criteria Creatinine clearance (CLCR) <30 mL/min, actively receiving probenecid or valproic acid, and the need for multiple surgical interventions that could affect microdialysis catheter placement
Methods Participants received tebipenem pivoxil hydrobromide 600 mg orally every 8 hours for three doses if CrCl was >50 mL/min, or 300 mg every 8 hours for patients with infections and CrCl of 30–50 mL/min. Patients with diabetic foot infections continued standard-of-care antibiotics throughout the study. Plasma and subcutaneous interstitial fluid samples were collected over the final 8-hour dosing interval using blood sampling and microdialysis, with catheters placed near the infected wound in patients or in the thigh of healthy volunteers. Tebipenem concentrations were analyzed to assess pharmacokinetic parameters, tissue penetration, and pharmacodynamic target attainment against Escherichia coli and Klebsiella pneumoniae. Adverse events were monitored through 72 hours after the final dose.
Duration Three doses administered every 8 hours (approximately 24-hour dosing period), with safety follow-up through 72 hours after the final dose.
Outcome Measures

Primary: Total plasma, free plasma, and interstitial fluid pharmacokinetics of tebipenem

Other: Safety and tolerability of tebipenem in healthy subjects and patients with DFI

Baseline Characteristics   Healthy subjects (n= 6) Infected patients with DFI (n= 6)
Age, years 34 ± 10 58 ± 8
Male 4 (67%) 5 (83%)
Height, cm 174 ± 13 179 ± 12
Weight, kg 90 ± 16 99 ± 18
BMI, kg/m2 29 ± 2 31 ± 5
Albumin g/dL 4.3 ± 0.3 3 ± 0.4
Hemoglobin A1C (%) ND 10.0 ± 1.9
PEDIS infection grade NA 3
CLCR, mL/min (IQR) 129.5 (118–144) 88 (76–104)
Abbreviations: BMI, body mass index; CLCR, creatinine clearance; IQR, interquartile range.
Results Pharmacokinetic parameter Healthy subjects (n= 6) Infected patients with DFI (n= 6)
Plasma fCmax, mg/L 3.74 ± 2.35 3.40 ± 2.86
Plasma Tmax, h 1.25 ± 0.61 2.83 ± 1.47
Plasma t½, h 0.88 ± 0.11 2.02 ± 1.32
Plasma CL/F, L/h 57.7 ± 16.6 36.2 ± 11.6
Plasma Vd/F, L 73.5 ± 24.9 109.2 ± 85.7
Tissue Cmax, mg/L 2.85 ± 2.15 2.73 ± 1.44
Tissue Tmax, h 2.09 ± 0.80 3.0 ± 1.26
Total plasma AUC0–8, mg·h/L 11.12 ± 3.10 18.54 ± 7.72
Free plasma AUC0–8, mg·h/L 5.61 ± 1.64 10.01 ± 4.81
Tissue AUC0–8, mg·h/L 5.99 ± 3.07 8.60 ± 2.88
Tissue penetration (%) 107.4 ± 42.7 90.0 ± 16.7
Pharmacokinetic/pharmacodynamic analyses indicated that tebipenem plasma and tissue exposures achieved the modeled 1-log bacterial kill target against Escherichia coli and Klebsiella pneumoniae using published MIC₉₀ values.
Adverse Events Tebipenem was well tolerated with no serious adverse events reported. In healthy subjects, one adverse event was reported pre-final dose and seven post-final dose, including a vasovagal episode and transient abnormal laboratory tests. In the patient cohort, mild leucocytosis and transient hypokalemia were reported.
Study Author Conclusions In conclusion, tebipenem had an acceptable safety profile and demonstrated excellent tissue distribution in healthy subjects and diabetic patients with ongoing foot infections following oral administration of tebipenem pivoxil hydrobromide 600 mg every 8 h. Integrating these findings with established pharmacodynamic and microbiological profiles suggests that oral tebipenem pivoxil hydrobromide could be a valuable option for the treatment of lower extremity infections in the diabetic population. Lastly, this study highlights the importance of conducting pharmacokinetic evaluation in the target infected population as they might have altered pharmacokinetic parameters.
Critique The small sample size and single-center design limit the generalizability of the findings. Additionally, the study evaluated pharmacokinetic parameters and tissue penetration rather than clinical efficacy, and patients with diabetic foot infections continued receiving standard-of-care antibiotics. Therefore, the findings do not establish the clinical effectiveness of tebipenem for treating diabetic foot infections.
Table 1 References:
[2] Abouelhassan Y, Fratoni AJ, Shepard AK, Nicolau DP, Asempa TE. Pharmacokinetics and soft-tissue distribution of tebipenem pivoxil hydrobromide using microdialysis: a study in healthy subjects and patients with diabetic foot infections. J Antimicrob Chemother. 2022;78(1):296-301. doi:10.1093/jac/dkac399
In Vitro and In Vivo Characterization of Tebipenem, an Oral Carbapenem
Design In vitro and in vivo characterization study
Objective To evaluate the microbiological activity and efficacy of tebipenem, an oral carbapenem, against multidrug-resistant Gram-negative pathogens, and to support its use as an oral treatment option for complicated urinary tract infections (cUTIs)
Methods

In vitro microbiological testing evaluated tebipenem activity against clinical bacterial isolates, including multidrug-resistant Gram-negative pathogens, using minimum inhibitory concentration (MIC) testing, time-kill assays, and postantibiotic effect assessments. Antibacterial activity was also evaluated under varying pH, inoculum sizes, atmospheric conditions, and in the presence of serum or human urine. Comparator antibiotics included meropenem, tigecycline, levofloxacin, ciprofloxacin, polymyxin B, and metronidazole.

In vivo efficacy was assessed using murine thigh, lung, and urinary tract infection models. Mice received oral tebipenem pivoxil at varying doses and intervals, with treatment initiated 2 hours after infection in the lung models and 24 hours after inoculation in the urinary tract infection models. Treatment duration varied by model, including 15–26 hours for lung infections and 3 days for urinary tract infections. Bacterial burden was assessed by quantitative cultures of infected tissues or urine, with colony-forming units (CFU) measured following treatment.

Duration Not specified
Outcome Measures Minimum inhibitory concentrations (MICs), bactericidal activity, postantibiotic effect, antibacterial activity under varying experimental conditions, bacterial burden (CFU) in murine thigh, lung, and urinary tract infection models
Results

In vitro testing demonstrated tebipenem activity against Gram-negative and Gram-positive pathogens, including extended-spectrum β-lactamase (ESBL)- and AmpC-producing Enterobacterales, with reduced activity against carbapenem-resistant isolates and Pseudomonas aeruginosa. Tebipenem demonstrated activity against anaerobic bacteria, with minimum inhibitory concentrations inhibiting 90% of isolates (MIC₉₀) ranging from 0.015 to 2 µg/mL, similar to meropenem. Time-kill assays demonstrated bactericidal activity against Escherichia coli and Klebsiella pneumoniae at 4–8 times the MIC within 4 hours, while the postantibiotic effect was approximately 0.4 hours. Antibacterial activity decreased with increasing bacterial inoculum and in the presence of 50% mouse serum, but no significant changes were observed with 10% or 50% human serum.

In murine infection models, oral tebipenem pivoxil produced dose-dependent reductions in bacterial burden. In the E. coli thigh infection model, bacterial burden decreased by 1.3–2.4 log₁₀ CFU/g at doses of 10–100 mg/kg. In the K. pneumoniae lung infection model, tebipenem reduced bacterial burden to pretreatment levels at 30 mg/kg once daily and below pretreatment levels at doses greater than 10 mg/kg every 8 hours, with efficacy comparable to meropenem and tigecycline. In the P. aeruginosa lung infection model, doses of at least 30 mg/kg every 8 hours reduced bacterial burden to pretreatment levels, with a maximum reduction of 2.6 log₁₀ CFU/g at 300 mg/kg every 8 hours. In murine urinary tract infection models, tebipenem produced dose-dependent reductions in bacterial burden in the kidneys, bladder, and urine, with reductions comparable to levofloxacin or ciprofloxacin at the evaluated doses.

Study Author Conclusions Microbiological data are presented here that demonstrate equivalency of tebipenem with intravenous carbapenems such as meropenem and support its use in infections in which the potency and spectrum of a carbapenem are desired. The results from standard in vitro microbiology assays as well as efficacy in several in vivo mouse infection models suggest that tebipenem-PI-HBr could be a valuable oral agent available to physicians for the treatment of infections, particularly those caused by antibiotic-resistant Gram-negative pathogens.
Critique The study provides preclinical evidence of tebipenem's antibacterial activity in vitro and efficacy in murine infection models, including nonurinary infections. However, findings from animal models may not translate directly to humans, and the study did not evaluate clinical efficacy or safety in patients. Further clinical studies are needed to establish its efficacy and safety for nonurinary indications.
Table 2 References:
[3] Cotroneo N, Rubio A, Critchley IA, Pillar C, Pucci MJ. In Vitro and In Vivo Characterization of Tebipenem, an Oral Carbapenem. Antimicrob Agents Chemother. 2020;64(8):e02240-19. Published 2020 Jul 22. doi:10.1128/AAC.02240-19

 

Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections

Design

Phase II, double-blind, comparative, dose-ranging clinical trial; abstract

Objective

To investigate the efficacy, safety, and pharmacokinetic/pharmacodynamic (PK-PD) parameters of oral tebipenem pivoxil in adults with otolaryngological infections and establish the recommended clinical dosage

Study Groups

450 mg/day group (n= 43)


500 mg/day group (n= 35)


900 mg/day group (n= 34)

Inclusion Criteria

Adults with otolaryngological infections caused by at least one of five specified bacterial pathogens: Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Moraxella catarrhalis, or Haemophilus influenzae.

Exclusion Criteria

Not specified in abstract

Methods

Participants received the Japanese tebipenem pivoxil formulation for 7 days in one of three dosing groups: 150 mg three times daily (450 mg/day), 250 mg twice daily (500 mg/day), or 300 mg three times daily (900 mg/day). Bacteriological efficacy was assessed by the disappearance of causative organisms, while pharmacokinetic/pharmacodynamic analyses examined the relationship between plasma tebipenem concentrations, minimum inhibitory concentrations, and bacteriological efficacy. Safety was assessed through adverse reactions and laboratory abnormalities.

Duration

Treatment duration: 7 days

Outcome Measures

Primary: Clinical efficacy at the end of treatment or discontinuation

Secondary: Bacteriological efficacy, pharmacokinetic/pharmacodynamic (PK/PD) parameters, safety

Baseline Characteristics

Patients had otolaryngological infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Moraxella catarrhalis, or Haemophilus influenzae. Additional baseline characteristics were not provided in the abstract.

Results

Among 112 patients included in the clinical efficacy analysis, efficacy rates were 72.1% (31/43), 88.6% (31/35), and 85.3% (29/34) in the 450 mg/day, 500 mg/day, and 900 mg/day groups, respectively. Bacteriological eradication rates were 92.2% (47/51), 94.7% (36/38), and 91.7% (33/36), respectively. All isolates of Streptococcus pneumoniae, including penicillin-resistant strains, Streptococcus pyogenes, and Moraxella catarrhalis were eradicated. The overall eradication rate for Haemophilus influenzae was 78.6%, with rates of 76.9%, 100%, and 66.7% across the respective dosing groups.

Pharmacokinetic/pharmacodynamic analysis of 124 isolates from 111 patients identified estimated target values of 10–20 for free-drug area under the concentration–time curve to minimum inhibitory concentration ratio (fAUC/MIC) and 4 for free-drug maximum concentration to MIC ratio (fCmax/MIC), while no clear relationship was observed between time above MIC and bacteriological efficacy.

Adverse Events

The incidence of adverse reactions involving clinical signs and symptoms was 28.8% (21/73), 35.8% (24/67), and 30.6% (22/72) in the 450 mg/day, 500 mg/day, and 900 mg/day groups, respectively. Abnormal laboratory test values were reported in 8.2% (6/73), 9.2% (6/65), and 9.9% (7/71) of patients, respectively. The authors reported no differences in adverse reaction rates among the treatment groups and concluded that the incidence was not dose-dependent.

Study Author Conclusions

Based on the above, we considered that tebipenem pivoxil at doses of 250 mg b.i.d (500 mg/day) promises high clinical usefulness for the treatment of otolaryngological infections in adults.

InpharmD Researcher Critique

The study evaluated the Japanese tebipenem pivoxil formulation, limiting direct applicability to the U.S.-approved tebipenem pivoxil hydrobromide formulation. Additionally, only the abstract is available in English, limiting assessment of the study methodology, baseline characteristics, and potential sources of bias.



Table 3 References:
[4] Baba S, Yamanaka N, Suzuki K, et al. Jpn J Antibiot. 2009;62(2):155-177.

 

Evaluation of safety and efficacy of tebipenem pivoxil granules for pediatric in pneumonia, otitis media and sinusitis

Design

Postmarketing surveillance study; abstract

N= 3,540

Objective

To evaluate the safety and efficacy of tebipenem pivoxil granules (Orapenem® fine granules 10% for pediatric) in pediatric patients with pneumonia, otitis media, or sinusitis through postmarketing surveillance

Study Groups

All patients (N= 3,540)

Inclusion Criteria

Pediatric patients with pneumonia, otitis media, or sinusitis who received tebipenem pivoxil granules (Orapenem®) during the postmarketing surveillance period (April 2010 to March 2013).

Exclusion Criteria

Not specified in abstract

Methods

Postmarketing surveillance of oral tebipenem pivoxil granules (Orapenem® fine granules 10% for pediatric) in pediatric patients with pneumonia, otitis media, or sinusitis. Of 3,547 enrolled patients, survey forms were collected for 3,540 patients, including 3,331 in the safety analysis, 2,844 in the efficacy analysis, 2,769 in the clinical efficacy analysis, and 461 in the bacteriological efficacy analysis. Assessments included adverse drug reactions, clinical efficacy, bacterial eradication, and treatment compliance.

Duration

Postmarketing surveillance period: April 2010 to March 2013

Outcome Measures

Incidence of adverse drug reactions, overall clinical efficacy and efficacy by infection type (pneumonia, otitis media, and sinusitis), bacterial eradication rates for Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, and treatment compliance

Baseline Characteristics

Patients were pediatric patients with pneumonia, otitis media, or sinusitis who received tebipenem pivoxil granules. Additional baseline characteristics, including age, sex, and disease severity, were not reported in the abstract.

Results

The overall clinical efficacy rate was 94.0% (2,604/2,769 patients), with efficacy rates of 95.6% (415/434) for pneumonia, 93.7% (1,389/1,482) for otitis media, and 93.6% (659/704) for sinusitis. Bacteriological eradication rates were 94.4% (134/142 strains) for Streptococcus pneumoniae, 92.2% (130/141 strains) for Haemophilus influenzae, and 97.8% (45/46 strains) for Moraxella catarrhalis. Treatment compliance was reported as good in 83.1% (2,767/3,331) of patients.

Adverse Events

Adverse drug reactions were reported in 9.97% (332/3,331) of patients, primarily gastrointestinal disorders, including diarrhea, reported in 9.52% (317/3,331). Diarrhea occurred in 313 patients (316 events), with recovery or remission reported in 94.9% (297/313) of affected patients. The authors reported that the diarrhea events were not clinically significant.

Study Author Conclusions

These results indicate that Orapenem® fine granules 10% for pediatric is a useful agent in pediatrics with pneumonia or otitis media, or sinusitis.

InpharmD Researcher Critique

This was an uncontrolled, observational postmarketing surveillance study, limiting conclusions regarding comparative efficacy. Additionally, the study evaluated the Japanese tebipenem pivoxil formulation, limiting direct applicability to the U.S.-approved tebipenem pivoxil hydrobromide formulation. Only the abstract was available in English, limiting assessment of the study methodology, patient characteristics, and potential sources of bias.



Table 4 References:
[5] Kataoka H, Kasahara H, Sasagawa Y, Matsumoto M, Shimada S. Jpn J Antibiot. 2016;69(1):53-76.
Good transfer of tebipenem into middle ear effusion conduces to the favorable clinical outcomes of tebipenem pivoxil in pediatric patients with acute otitis media
Design

Prospective study

N= 23

Objective To assess the pharmacokinetic profile of tebipenem in middle ear effusion and to examine the clinical efficacy of tebipenem pivoxil by calculating the values of the pharmacokinetic-pharmacodynamic parameters (AUC/MIC, Cmax/MIC, and T [ MIC) of tebipenem at the site of action
Study Groups All patients (N= 23)
Inclusion Criteria Pediatric outpatients diagnosed with acute otitis media (AOM) based on the presence of middle ear effusion and obvious reddening of the eardrum
Exclusion Criteria Not specified
Methods Ear discharge or nasopharyngeal swabs were collected before treatment for bacterial identification and minimum inhibitory concentration (MIC) testing. Patients received oral tebipenem pivoxil 6 mg/kg twice daily for 5 days. On treatment day 2, blood and middle ear effusion samples were collected from 20 patients to measure tebipenem concentrations using liquid chromatography–tandem mass spectrometry (LC-MS/MS). Pharmacokinetic parameters were estimated using Bayesian analysis, and pharmacokinetic/pharmacodynamic (PK/PD) parameters, including AUC/MIC, Cmax/MIC, and time above MIC, were calculated. Clinical efficacy was assessed in 17 patients at treatment completion or the following day, with healing defined as resolution of middle ear effusion, tympanic membrane redness, and earache.
Duration April through August 2010
Outcome Measures Pharmacokinetic profile of tebipenem in middle ear effusion; clinical efficacy of tebipenem pivoxil; healing rate
Baseline Characteristics   All patients (N= 23)
Age, years 1.7 ± 1.1
Body weight, kg 10.8 ± 2.6
Simple AOM 19 cases
Recurrent otitis media 4 cases
Severe otitis media 21 cases
Moderate otitis media 2 cases
Results   All patients (N= 23)
Healing rate 94.1% (16/17)
Cmax in plasma 5.3 ± 1.6 µg/ml
AUC0–∞ in plasma 7.9 ± 0.2 µg h/ml
Cmax in middle ear effusion 1.2 ± 0.1 µg/ml
AUC0–∞ in middle ear effusion 2.8 ± 0.4 µg h/ml
The maximum tebipenem concentrations (Cmax) in plasma and middle ear effusion were 5.3 ± 1.6 µg/mL and 1.2 ± 0.1 µg/mL, respectively, with corresponding area under the concentration-time curve (AUC₀–∞) values of 7.9 ± 0.2 and 2.8 ± 0.4 µg·h/mL. The middle ear effusion-to-plasma ratios were 0.23 for Cmax and 0.36 for AUC₀–∞. The minimum inhibitory concentrations inhibiting 90% of isolates (MIC₉₀) were 0.06 µg/mL for Streptococcus pneumoniae and 1 µg/mL for Haemophilus influenzae. Clinical healing was achieved in 94.1% (16/17) of patients, including 100% (8/8) with S. pneumoniae and 92.9% (13/14) with H. influenzae. The single patient who did not achieve healing.
Adverse Events Not specified
Study Author Conclusions In conclusion, the good transfer of tebipenem into the effusion corroborated the known high rate of clinical efficacy of tebipenem pivoxil for patients with AOM and the low incidence of recurrence. The results from the present study suggested positive correlations between plasma and middle ear effusion concentrations of tebipenem and between the middle ear effusion concentrations of tebipenem and the clinical effects of tebipenem pivoxil. Further study is required to validate the relationship between the AUC/MIC and the healing rate of tebipenem pivoxil in pediatric patients with AOM.
Critique The study provides human pharmacokinetic data demonstrating tebipenem penetration into middle ear effusion, along with favorable clinical outcomes in pediatric patients with acute otitis media. However, the small sample size, lack of a comparator group, and limited clinical efficacy population (17 patients) restrict the strength and generalizability of the findings. Additionally, adverse event data were not reported, and the study evaluated the Japanese tebipenem pivoxil formulation, limiting direct applicability to the U.S. formulation.
Table 5 References:
[6] Sugita R. Good transfer of tebipenem into middle ear effusion conduces to the favorable clinical outcomes of tebipenem pivoxil in pediatric patients with acute otitis media. J Infect Chemother. 2013;19(3):465-471. doi:10.1007/s10156-012-0513-5